Pure Global AI
NCT03070704Withdrawn

Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
Novo Nordisk A/SClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes,Diabetes Mellitus, Type 2
Drug/Device/Intervention
insulin degludec/liraglutide
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Novo Nordisk A/S
Timeline & enrollment
Phase
N/A
Start date
Aug 16, 2017
End date
Aug 16, 2019
Enrollment
0 participants
Primary outcome

Incidence of treatment emergent Adverse Events (AEs)

Summary

This study is conducted in Asia. The aim of this study is to evaluate long term safety and
 efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03070704
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03070704 through Pure Global AI's free database. This phase not specified trial is sponsored by Novo Nordisk A/S and is currently Withdrawn. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 0 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.